Welcome to our dedicated page for Omnicell Com news (Ticker: OMCL), a resource for investors and traders seeking the latest updates and insights on Omnicell Com stock.
Omnicell, Inc. (NASDAQ: OMCL) is a healthcare technology company focused on intelligent medication management, and the OMCL news page on Stock Titan aggregates company-specific updates that matter to investors and healthcare observers. Omnicell describes itself as a leader in transforming the pharmacy and nursing care delivery model, with solutions that combine automation, AI-enabled intelligence, and expert services to support clinical, operational, and financial outcomes across all settings of care.
News related to Omnicell often centers on financial results, product innovation, and strategic developments. The company regularly issues earnings releases and guidance updates, discussing performance across categories such as connected devices, technical services, SaaS and Expert Services, and consumables. Press releases also cover events like conference presentations, investor Q&A sessions, and participation in industry meetings, providing context on how management communicates its strategy and outlook.
Product and technology announcements are another key theme in OMCL news. Examples include the launch of Omnicell Titan XT, an enterprise automated dispensing system powered by the OmniSphere cloud platform, and updates on OmniSphere certifications and capabilities. Omnicell also highlights initiatives such as specialty pharmacy services, URAC Health Care Management Certification, and innovation-focused events like Omnicell Illuminate and the IV TRUST Summit, which showcase developments in robotics, smart devices, software workflows, and data and analytics.
By following OMCL news, readers can monitor how Omnicell advances its vision of autonomous medication management, how it positions its solutions for health systems, retail and specialty pharmacies, and how management addresses risks and opportunities in a regulated healthcare environment. The Stock Titan news feed helps users track these announcements in one place for ongoing reference.
Summary not available.
Summary not available.
Summary not available.
Omnicell, a leader in medication management, has partnered with Long Island University to open the Center for Innovative Medication Management (CIMM) in Brooklyn, New York. This state-of-the-art facility aims to enhance pharmacy education through advanced technology and analytics. The initiative allows pharmacy students to gain hands-on experience with medication management technologies, including robotics and software aimed at optimizing medication inventory. This strategic collaboration will also train Omnicell's operational teams, reinforcing the company’s commitment to improving pharmaceutical care delivery. The inaugural classes of the CIMM are set to commence in Summer 2023, emphasizing the importance of technology in preparing future pharmacy leaders.
Omnicell, a provider of medication management solutions, will release its first quarter 2023 financial results on May 2, 2023, after market close.
The company will host a conference call at 4:30 p.m. ET that same day to discuss these results. Interested parties can participate via phone or access a link to the live and archived webcast on the company's Investor Relations page.
Since 1992, Omnicell has focused on transforming pharmacy care delivery, aiming to improve outcomes and reduce costs through advanced automation and analytics. Its services support healthcare facilities in managing medications efficiently, enhancing patient safety, and reducing hospital readmissions.
Omnicell reported its fiscal year 2022 results, revealing total GAAP revenues of $1.296 billion, a 14% increase from 2021. However, fourth-quarter GAAP revenues decreased by 4% year-over-year, reflecting ongoing macroeconomic challenges. The company ended the year with over 150 long-term contracts with major U.S. health systems and a backlog of $1.215 billion. Notably, the Chief Financial Officer will step down on July 1, 2023. For 2023, Omnicell projects bookings between $1.000 billion to $1.100 billion and total revenues between $1.150 billion to $1.190 billion.
Omnicell, Inc. (NASDAQ: OMCL) is set to release its financial results for the fourth quarter and full year 2022 on February 28, 2023, after market close. A conference call is scheduled for 4:30 p.m. ET on the same day to discuss these results. Interested parties can listen to the call by dialing (888) 440-4318 in the U.S. or (267) 764-0566 internationally. Omnicell, established in 1992, focuses on transforming pharmacy care delivery through automation and technology, ultimately aiming to improve outcomes and lower costs.
Summary not available.
Omnicell, a leader in medication management, will present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, at 8:15 a.m. Pacific Time. The presentation will be available via live and archived webcasts on Omnicell's website. Established in 1992, Omnicell focuses on enhancing pharmacy care delivery through automation and technology, aiming to improve patient safety and operational efficiency for healthcare providers. Their innovative solutions help reduce medication errors and hospital readmissions across North America and the UK.
Omnicell is set to showcase its Advanced Services at the ASHP Midyear Clinical Meeting from December 5-8, 2022, in Las Vegas. These services include IV Compounding, Central Pharmacy Dispensing, Inventory Optimization, Retail Pharmacy, and Specialty Pharmacy Services, all aimed at enhancing medication management efficiency and patient safety. The company's strategy focuses on integrating technology to improve clinical outcomes and create economic value for health systems. Omnicell's efforts could potentially lead to improved operational efficiency and reduced medication errors across healthcare settings.